{"prompt": "['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', \"Identified P. aeruginosa isolates should be collected and stored in the investigator's\", \"institution and might potentially undergo further for future testing at GSK Biologicals'\", 'laboratory or at a laboratory designated by GSK Biologicals.', 'In addition, some respiratory viral pathogens (such as HRVthinovirus) may will be', \"quantified in stored sputum samples (or subset) using RT-PCR at GSK Biologicals'\", 'laboratory or at a laboratory designated by GSK Biologicals.', 'Table 8 Microbiology', 'System', 'Component', 'Method', 'Scale', 'Laboratory', 'Quality assessment', 'Fresh sputum', 'Please refer to SPM and/or', 'Gram staining', 'Qualitative/', 'Investigator institution or', 'Central Laboratory Manual', 'semi-', 'GSK designated', 'for components tested', 'quantitative', 'laboratory', 'Bacterial pathogen identification', 'Fresh sputum', 'Respiratory bacterial', 'Standard', 'Qualitative', \"Investigator's institution\", 'pathogens', 'bacteriological', 'and/or at a laboratory', '(including H. influenzae,', 'culture and', 'Semi-', 'designated by GSK', 'S. pneumoniae,', 'standard', 'quantitative', 'Biologicals', 'M. catarrhalis, S. aureus,', 'identification', 'P. aeruginosa,', 'methods including', 'K. pneumoniae and A.', 'semi-quantitative', 'baumannii)', 'culture', 'H. influenzae isolates', 'H. influenzae species', 'Molecular', 'Qualitative', 'GSK Biologicals', 'of positive', 'confirmation and when', 'techniques such', 'laboratory* or designated', 'H. influenzae culture', 'possible Hi/NTHi', 'as differentiation', 'laboratory', 'plates', 'differentiation', 'PCR', 'Sample collection for', 'potential further', 'characterisation', 'H. influenzael', 'H.haomolyticus', 'differentiation', 'M.catarrhalis', 'Sample collection forisolate', 'Molecular', 'Qualitative', 'GSK Biologicals', 'isolates of positive', 'characterisation', 'techniques', 'laboratory*or', 'M.catarrhalis', 'designated-laboratory', 'culture plates', 'P.aeruginosa', 'Sample collection for isolate', 'Molecular', 'Qualitative', 'GSK Biologicals', 'isolates of positive', 'characterisation', 'techniques', 'laboratory*or', 'Paeruginosa-culture', 'designated-laboratory', 'plates', 'Viral pathogen identification', 'Stored sputum', 'Respiratory viral pathogens', 'Multiplex-PCR', 'Qualitative', 'GSK Biologicals', '(including RSV,', 'and/or', 'laboratory or designated', 'parainfluenza virus,', 'quantitative', 'laboratory', 'enterovirus/ HRV/hinovirus,', 'metapneumovirus, influenza', 'virus, adenovirus, bocavirus', 'and coronavirus)', '* GSK Biologicals laboratory refers to the Clinical Laboratory Sciences (CLS) in Wavre, Belgium; Rixensart, Belgium;', 'Marburg, Germany.', '19-OCT-2018', '109', '5661ebdab2e949f7a1f1bc2071b9dec72aceccf']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Stored frozen sputum samples (either in dithiothreitol [DTT] and/or in DTT', 'supplemented with skim milk, tryptone, glucose, and glycerine [STGG] medium) might', 'be used for assay development, such as assays for diagnostic purpose or for microbiome', 'analysis and/or for assay validation/characterization purpose and/or quality control.', 'Stored frozen sputum samples (in DTT supplemented with skim milk, tryptone, glucose,', 'and glycerine [STGG] medium) might be collected when possible for potential assay', 'development/validation purpose.', 'Additional testing on stored sputum samples (such as, but not limited to, K. pneumoniae', 'and A. baumannii PCR detection, quantitative PCR for other bacterial and/or viral', 'pathogens, further characterisation of virus such as rhinovirus typing, pathogen', 'genome/gene sequencing, pathogen quantitative/qualitative serotype-specific PCR,', 'multilocus sequence typing, microarray typing, 16sRNA analysis) or on H. influenzae, M.', 'catarrhalis and P. aeruginosa bacterial isolates (such as agglutination assays, further', 'strain characterisation using new molecular biology tools) may be done during the study', 'or after study completion, should these data be required for accurate interpretation of the', 'study data and/ or for further research related to respiratory diseases and/ or should such', \"test(s) become available at GSK Biologicals' laboratory or a laboratory designated by\", 'GSK.', 'Section 7.2.1 Time periods for detecting and recording AEs and SAEs', 'Table 10 Reporting period for SAE and AEs leading to withdrawal', 'Study activity', 'Screening', 'Visit 1', 'Visit 2', 'Visit 3', 'AECOPD', 'Study', 'Visit', 'Visit', 'Conclusion', 'Pre-Month 0', 'M 0', 'M 6', 'M 12', 'Within 96', 'hours of', 'onset', 'symptoms', 'AEs/SAEs', 'related to', 'study', 'participation*', 'AEs leading to', 'withdrawal', 'from the study', '*Study participation: Specific procedures required by study participation.', 'Synopsis and Section 9.1.3', 'Human Rhinovirus (HRV) Viral-load measured by PCR in COPD and during', 'AECOPD.', '19-OCT-2018', '110', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']\n\n###\n\n", "completion": "END"}